Thus, for patients with low CD163+macrophage infiltration in pre-treatment biopsy samples, diagnostic imaging should be performed frequently during chemotherapy to avoid missing the optimal timing for CS, and CS should be aggressively considered as a treatment option if curative resection is deemed feasible. This evidence concerns the gene CD163 and Cowden syndrome 1.